Apolipoprotein A-I [ApoA1] (human):Fc (human) (rec.)
|Synonyms||Apolipoprotein A1; ApoA-I; Apo-AI|
|Source/Host||HEK 293 cells|
The extracellular domain of human ApoA1 (aa 25-267) is fused to the N-terminus of the Fc region of human IgG1.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
Reconstitute with sterile water to a concentration of 100μg/ml.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
NCBI reference AAH05380.1: ApoA1 (human)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Apolipoprotein A-I [Apolipoprotein A1; ApoA1] is a 28kDa glycoprotein that is the major protein component of high density lipoprotein (HDL) particles. ApoA1is involved in the esterification of cholesterol as a cofactor of lecithin-cholesterol acyltransferase (LCAT), which is responsible for the formation of most plasma cholesteryl esters, and thus plays a major role in cholesterol efflux from peripheral cells. Therefore, as a major component of the HDL complex, ApoA1 plays a central role in the reverse transport of cholesterol from peripheral tissues to the liver. Upon HDL particles return to the liver, ApoA1 binds to the scavenger receptor SR-B1 and the &beta-;chain of ATP synthase on hepatocytes. Hepatocytes internalize the particles and pass the cholesterol into bile for excretion. Polymorphisms of ApoA1 are associated with dysregulation of HDL levels and cholesterol homeostasis. Genetic defects of ApoA1 have been associated with HDL deficiencies, including Tangier disease and with systemic non-neuropathic amyloidosis. ApoA1, either as a free molecule or in lipidated particulate form, induces the release of insulin from pancreatic islets in a process that is dependent on ABCA1 and SR-B1. ApoA1 has also been characterized as a prostacyclin stabilizing factor and thus may have an anticlotting effect.